Complete and sustained response after peptide receptor radionuclide therapy in a 66-year-old Filipino male with metastatic pancreatic neuroendocrine tumor: A case report
- Author:
Carl Joshua M. Chianpian
1
;
Patricia A. Bautista-Peñalosa
1
;
Carl Johnry J. Santos
1
;
Irene S. Bandong
1
Author Information
1. Department of Nuclear Medicine and Theranostics, St. Lukes Medical Center, Quezon City
- Publication Type:Journal Article
- Keywords:
Peptide receptor radionuclide therapy
- MeSH:
Receptors, Peptide;
Pancreatic Neoplasms;
Neuroendocrine Tumors
- From:
The Philippine Journal of Nuclear Medicine
2023;18(2):8-13
- CountryPhilippines
- Language:English
-
Abstract:
The introduction of peptide receptor radionuclide therapy (PRRT) to the Philippines has allowed for novel
approaches in the management of neuroendocrine tumors (NETs). This case report details the management of a
66-year-old Filipino man diagnosed with metastatic pancreatic NET after biopsy and staging with Ga-68
DOTATATE PET-CT. After poor response to somatostatin analogue therapy, the patient was advised to undergo
PRRT. Upon completing four cycles of PRRT with Lu-177 DOTATATE, the metastatic hepatic lesions showed
resolution and the pancreatic tail tumor exhibited regression, allowing the patient to undergo surgical resection
of the primary tumor. On follow-up, he was declared to be in remission with good quality of life and no imaging
evidence of recurrence. The case underscores the diagnostic and therapeutic utility of radiolabeled
somatostatin analogues along with the importance of a multidisciplinary approach in the management of an
initially unresectable metastatic pancreatic NET
- Full text:18 (2) article 1.pdf
